. An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease. Front Pharmacol. 2022;13:991982. Epub 2022 Oct 14 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.